RA Session II served as the CEO of Taysha Gene Therapies, Inc. from November 2020 to December 2022 before transitioning to a board member role. He has a background deep in the biotech industry, previously holding senior positions at leading...

RA Session II served as the CEO of Taysha Gene Therapies, Inc. from November 2020 to December 2022 before transitioning to a board member role. He has a background deep in the biotech industry, previously holding senior positions at leading companies like AveXis and BridgeBio Pharma. During his time at Taysha, he oversaw significant growth and strategic directions for the company focused on gene therapy. RA’s compensation in 2021 reached a high of approximately $4.57 million, largely boosted by substantial performance bonuses and stock awards, reflecting his impact on the company. Remarkably, he was granted over 769,000 shares of stock that were valued significantly at the end of 2020, indicating his vested interest in the company’s success. Interestingly, after his resignation from the CEO role, RA stepped away from the Board in March 2023, marking a significant change in Taysha's leadership.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Taysha Gene Therapies, Inc. CEOs

T

RA Session II

Ex-CEO of Taysha Gene Therapies, Inc.

Sector of Economy

Healthcare

CEO of Taysha Gene Therapies, Inc. for

2 years 0 months (Nov 2020 - Dec 2022)

Previous Experience

Unknown

Rivals

Competitors/colleagues of RA Session II

H

David O'Reilly

CEO of Howard Hughes

2023 Compensation

Stock

$0.00

Salary

$750.00K

Bonus

$1.73M

Other

$170.97K

Total Holdings

$299.21M

Holdings

See how much did RA Session II make over time.

At the peak of his career at Taysha Gene Therapies, RA Session II held a significant amount of common stock, nearly 9.54 million shares, accounting for about 24.8% of the company's total shares. His holdings reflected the company's progress and...

At the peak of his career at Taysha Gene Therapies, RA Session II held a significant amount of common stock, nearly 9.54 million shares, accounting for about 24.8% of the company's total shares. His holdings reflected the company's progress and growth potential. However, following his resignation, it was noted that his unvested equity awards ceased to vest, highlighting the risks associated with stock-based compensation. Yet, his substantial stock ownership demonstrated his belief and commitment to the company's mission during his tenure. He also participated in performance-based earnings, with a notable bonus of $271,400 awarded in 2022, showcasing the company's valuation during that time.

Loading...

Total Stock Sold

$383.46K

TSHA

$383.46K

549,095 TSHA shares

What if they kept their stock?

If RA Session II didn't sell their stock, today they would have:
Extra TSHA549,095 shares worth $13.21M.
This is 3,345.27% and $12.83M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of RA Session II.

TSHA

$60.46K

TSHA at $0.70/share

Jul 12, 2023

Sale

TSHA

$20.12K

TSHA at $0.70/share

Jun 22, 2023

Sale

TSHA

$307.19K

TSHA at $0.71/share

Jun 20, 2023

Sale

TSHA

$526.59K

TSHA at $12.39/share

Nov 23, 2021

Purchase

Compensation History

See how much did RA Session II make over time.

In 2022, RA Session II reported total compensation of approximately $1.8 million, which included a salary of $537,939, a performance bonus of $271,400, and additional benefits valued at roughly $173. The structure of his compensation revealed a focus on aligning executive interests with company performance, rewarding him based on both corporate and individual successes. This emphasis on performance is further showcased by the 2021 compensation package, where his total was around $4.57 million, heavily influenced by stock awards that reflected the company’s value at the time. Since joining Taysha, his compensation packages reflected a balance between base salary and larger stock-based rewards, giving him a stake in the company's future.

Year

2022

Total Compensation

$809.51K

Salary

$537.94K

Board Justification

The compensation philosophy is designed to attract and retain talented executives while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$271.40K

Board Justification

Discretionary performance bonuses based on overall corporate and individual executive achievements in 2021, approved on November 10, 2022.

Other

$173.00

Board Justification

Life insurance premiums for employee benefit.

Restricted Stock

$1.95(251.3K common stock)

Board Justification

Vested shares awarded in lieu of a performance bonus that was originally offered as an option to purchase shares, following the cancellation of the option on March 6, 2023.

Performance Metrics

Performance metrics include individual and corporate performance objectives established by the Board of Directors.

Other Taysha Gene Therapies, Inc. CEOs

Here are other CEOs of Taysha Gene Therapies, Inc.

Sean Nolan

CEO of Taysha Gene Therapies, Inc.

December 2022 - Present